Building a better aspirin: Gaseous solutions to a century-old problem

British Journal of Pharmacology

Volumn 152, Issue 4, 2007, Pages 421-428

  Wallace, J L ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Arthritis; Cyclooxygenase; Hydrogen sulphide; Inflammation; Inflammatory bowel disease; Nitric oxide; Nonsteroidal anti inflammatory drugs; Pain; Prostaglandin

Indexed keywords

ABT 429; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLUNISOLIDE; FLURBIPROFEN; GLUCOCORTICOID; HYDROGEN SULFIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOPROFEN; LUMIRACOXIB; MESALAZINE; MESALAZINE DERIVATIVE; NAPROXCINOD; NAPROXEN; NAPROXEN DERIVATIVE; NCX 2216; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARACETAMOL DERIVATIVE; PRAVASTATIN; PREDNISONE; PROSTAGLANDIN; ROFECOXIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BONE DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLITIS; COLON CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DYSPEPSIA; ENTERITIS; ENZYME INHIBITION; EXPERIMENTAL MODEL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; HYPOTENSION; INFLAMMATION; LEUKOCYTE ADHERENCE; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; PAIN; PATHOGENESIS; PHASE 3 CLINICAL TRIAL; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; RHEUMATOID ARTHRITIS; STOMACH BLOOD FLOW; STOMACH MUCOSA; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CHEMISTRY, PHARMACEUTICAL; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYDROGEN SULFIDE; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; STOMACH ULCER;

EID: 35348904437     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707396     Document Type: Conference Paper

References (96)

1. Asako H, Kubes P, Wallace JL, Gaginella T, Wolf RE, Granger DN (1992a). Indomethacin-induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. Am J Physiol 262: G903-G908.
2. Asako H, Kubes P, Wallace JL, Wolf RE, Granger DN (1992b). Modulation of leukocyte adhesion to rat mesenteric venules by aspirin and salicylate. Gastroenterology 103: 146-152.
3. Bak AW, McKnight W, Li P, Del Soldato P, Calignano A, Cirino G et al. (1998). Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci 62: PL367-PL373.
4. Bhatia M, Wong FL, Fu D, Lau HY, Moochhala SM, Moore PK (2005). Role of hydrogen sulphide in acute pancreatitis and associated lung injury. FASEB J 19: 623-625.
5. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520-1528.
6. Brzozowska I, Targosz A, Sliwowski Z, Kwiecien S, Drozdowicz D, Pajdo R et al. (2004). Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor. J Physiol Pharmacol 55: 773-790.
7. Cirino G, Wheeler-Jones CP, Wallace JL, Del Soldato P, Baydoun AR (1996). Inhibition of inducible nitric oxide synthase expression by novel nonsteroidal anti-inflammatory derivatives with gastrointestinal-sparing properties. Br J Pharmacol 117: 1421-1426.
8. Davies NM, Roseth AG, Appleyard CB, McKnight W, Del Soldato P, Calignano A et al. (1997b). NO-naproxen vs naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther 11: 69-79.
9. Davies NM, Sharkey KA, Asfaha S, MacNaughton WK, Wallace JL (1997a). Aspirin causes rapid up-regulation of cyclo-oxygenase-2 expression in the stomach of rats. Aliment Pharmacol Ther 11: 1101-1108.
10. ATP channels. J Pharmacol Exp Ther 316: 325-335.
11. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G et al. (2006b). 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)- phenyl ester (ATB-429), a hydrogen sulphide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther 319: 447-458.
12. Douthwaite AH, Lintott SAM (1938). Gastroscopic observation of the effect of aspirin and certain other substances on the stomach. Lancet 2: 1222-1225.
13. Elliott SN, McKnight W, Cirino G, Wallace JL (1995). A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 109: 524-530.
14. Ferreira SH (1993). The role of interleukins and nitric oxide in the mediation of inflammatory pain and its control by peripheral analgesics. Drugs 46 (Suppl 1): 1-9.
15. Fiorucci S, Antonelli E, Brancaleone V, Sanpaolo L, Orlandi S, Distrutti E et al. (2003). NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J Hepatol 39: 932-939.
16. Fiorucci S, Antonelli E, Distrutti E, Del Soldato P, Flower RJ, Clark MJ et al. (2002a). NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc Natl Acad Sci USA 99: 15770-15775.
17. Fiorucci S, Antonelli E, Distrutti E, Rizzo G, Mencarelli A, Orlandi S et al. (2005). Inhibition of hydrogen sulphide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology 129: 1210-1224.
18. Fiorucci S, Antonelli E, Mencarelli A, Palazzetti B, Alvarez-Miller L, Muscara M et al. (2002b). A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway. Br J Pharmacol 135: 589-599.
19. Fiorucci S, Antonelli E, Santucci L, Morelli O, Miglietti M, Federici B et al. (1999a). Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology 116: 1089-1106.
20. Fiorucci S, Distrutti E, Cirino G, Wallace JL (2006). The emerging roles of hydrogen sulphide in the gastrointestinal tract and liver. Gastroenterology 131: 259-271.
21. Fiorucci S, Orlandi S, Mencarelli A, Caliendo G, Santagada V, Distrutti E et al. (2007). Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol 150: 996-1002.
22. Fiorucci S, Santucci L, Federici B, Antonelli E, Distrutti E, Morelli O et al. (1999b). Nitric oxide-releasing NSAIDs inhibit interleukin-1β converting enzyme-like cysteine proteases and protect endothelial cells from apoptosis induced by TNFα. Aliment Pharmacol Ther 13: 421-435.
23. Fiorucci S, Santucci L, Gresele P, Faccino RM, del Soldato P, Morelli A (2003b). Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124: 600-607.
24. Fiorucci S, Santucci L, Wallace JL, Sardina M, Romano M, del Soldato P et al. (2003c). Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci USA 100: 10937-10941.
25. Flower RJ, Vane JR (1972). Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 240: 410-411.
26. Futter LE, al-Swayeh OA, Moore PK (2001). A comparison of the effect of nitroparacetamol and paracetamol on liver injury. Br J Pharmacol 132: 10-12.
27. Gilroy DW, Lawrence T, Perretti M, Rossi AG (2004). Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 3: 401-416.
28. Goubern M, Andriamihaja M, Nubel T, Blachier F, Bouillard F (2007). Sulfide, the first inorganic substrate for human cells. FASEB J 21: 1699-1706.
29. Gresele P, Migliacci R, Procacci A, De Monte P, Bonizzoni E (2007). Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. Thromb Haemost 97: 444-450.
30. Hawkey C, Jones JI, Atherton CT, Skelly MM, Bebb JR, Fagerholm U et al. (2003). Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 52: 1537-1542.
31. Hippisley-Cox J, Coupland C, Logan R (2005). Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 331: 1310-1316.
32. Hogaboam CM, Befus AD, Wallace JL (1993). Modulation of rat mast cell reactivity by IL-β. Divergent effects on nitric oxide and platelet-activating factor release. J Immunol 151: 3767-3774.
33. Hu LF, Wong PT, Moore PK, Bian JS (2007). Hydrogen sulphide attenuates lipopolysaccharide-induced inflammation by inhibition of p38 mitogen-activated protein kinase in microglia. J Neurochem 100: 1121-1128.
34. Hyun E, Bolla M, Steinhoff M, Wallace JL, Soldato PD, Vergnolle N (2004). Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. Br J Pharmacol 143: 618-625.
35. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM et al. (2002). Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22: 2246-2254.
36. Jüni P, Rutjes JP, Dieppe PA (2002). Are selective COX 2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ 324: 1287-1288.
37. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C (2006). Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302-1308.
38. Kitagawa H, Takeda F, Kohei H (1990). Effect of endothelium-derived relaxing factor on the gastric lesion induced by HCl in rats. J Pharmacol Exp Ther 253: 1133-1137.
39. Kubes P, Suzuki M, Granger DN (1991). Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88: 4651-4655.
40. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (1991). TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266: 12866-12872.
41. Lanas A, Bajador E, Serrano P, Fuentes J, Carreno S, Guardia J et al. (2000). Nitrovasodilators, low-dose aspirin, other nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343: 834-839.
42. Li L, Bhatia M, Zhu YZ, Zhu YC, Ramnath RD, Wang ZJ et al. (2005). Hydrogen sulphide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. FASEB J 19: 1196-1198.
43. Li L, Rossoni G, Sparatore A, Lee LC, Del Soldato P, Moore PK (2007). Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic Biol Med 42: 706-719.
44. Lohmander LS, McKeith D, Svensson O, Malmenäs M, Bolin L, Kalla A et al. (2005). A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 64: 449-456.
45. Ma L, Del Soldato P, Wallace JL (2002). Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance. Proc Natl Acad Sci USA 99: 13243-13247.
46. MacNaughton WK, Cirino G, Wallace JL (1989). Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci 45: 1869-1876.
47. Magee EA, Richardson CJ, Hughes R, Cummings JH (2000). Contribution of dietary protein to sulfide production in the large intestine: an in vitro and a controlled feeding study in humans. Am J Clin Nutr 72: 1488-4894.
48. Mariggio MA, Minunno V, Riccardi S, Santacroce R, De Rinaldis P, Fumarulo R (1998). Sulfide enhancement of PMN apoptosis. Immunopharmacol Immunotoxicol 20: 399-408.
49. Michael Hill C, Sindet-Pederson S, Seymour RA, Hawkesford JE, Coulthard P, Lamey PJ et al. (2006). Analgesic efficacy of the cyclooxygenase- inhibiting nitric oxide donor AZD3582 in post-operative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies. Clin Ther 28: 1279-1295.
50. Milby TH, Baselt RC (1999). Hydrogen sulfide poisoning: clarification of some controversial issues. Am J Ind Med 35: 192-195.
51. Mitchell JA, Warner TD (2006). COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 5: 75-86.
52. Momi S, Emerson M, Paul W, Leone M, Mezzasoma AM, Del Soldato P et al. (2000). Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. Eur J Pharmacol 397: 177-185.
53. Muscará MN, Lovren F, McKnight W, Dicay M, Del Soldato P, Triggle CR et al. (2001). Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. Br J Pharmacol 133: 1314-1322.
54. Muscará MN, Lovren F, McKnight W, Triggle CR, Cirino G, Wallace JL (2000). Anti-hypertensive properties of a nitric oxide-releasing naproxen derivative in 2-kidney, 1-clip rats. Am J Physiol 279: H528-H535.
55. Muscará MN, McKnight W, Wallace JL (1998). Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life Sci 62: PL235-PL240.
56. Ortiz MI, Castaneda-Hernandez G, Rosas R, Vidal-Cantu GC, Granados-Soto V (2001). Evidence for a new mechanism of action of diclofenac: activation of K+ channels. Proc West Pharmacol Soc 44: 19-21.
57. Paul-Clark M, Del Soldato P, Fiorucci S, Flower RJ, Perretti M (2000). 21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti-inflammatory properties. Br J Pharmacol 131: 1345-1354.
58. Paul-Clark MJ, Mancini L, Del Soldato P, Flower RJ, Perretti M (2002). Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc Natl Acad Sci USA 99: 1677-1682.
59. Rigas B, Williams JL (2002). NO-releasing NSAIDs and colon cancer chemoprevention: A promising novel approach. Int J Oncol 20: 885-990.
60. Robert A, Nezamis JE, Lancaster C, Hanchar AJ (1979). Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 77: 433-443.
61. 2. Intravenous, oral and intrajejunal administration. Gastroenterology 70: 359-370.
62. Rossiello MR, Momi S, Caracchini R, Giannini S, Guglielmini G, Monopoli A et al. (2005). A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. J Thromb Haemost 3: 2554-2562.
63. Rossoni G, Berti M, De Gennaro Colonna V, Del Soldato P, Berti F (2000). myocardial protection by the nitroderivative of aspirin, NCX 4016: in vitro and in vivo experiments in the rabbit. Ital Heart J 1: 146-155.
64. Rossoni G, Manfredi B, de Gennaro Colonna V, Bernareggi M, Berti F (2001). The nitroderivative of aspirin, NCX 4016, reduces infarct size caused by myocardial ischemia-reperfusion in the anesthetized rat. J Pharmacol Exp Ther 297: 380-387.
65. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E et al. (2004). Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364: 665-674.
66. Steen KS, Lems WF, Aertsen J, Bezemer D, Dijkmans BA (2001). Incidence of clinically manifest ulcers and their complications in patients with rheumatoid arthritis. Ann Rheum Dis 60: 443-447.
67. Tanaka A, Araki H, Komoike Y, Hase S, Takeuchi K (2001). Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal sulphide anti-inflammatory drugs. J Physiol Paris 95: 21-27.
68. Tanaka A, Hase S, Miyazawa T, Takeuchi K (2002). Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 300: 754-761.
69. Tang G, Wu L, Liang W, Wang R (2005). Direct stimulation of K(ATP) channels by exogenous and endogenous hydrogen sulphide in vascular smooth muscle cells. Mol Pharmacol 68: 1757-1764.
70. Turesin F, del Soldato P, Wallace JL (2003). Enhanced anti-inflammatory potency of a nitric oxide-releasing prednisolone derivative in the rat. Br J Pharmacol 139: 966-972.
71. Vane JR (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 231: 232-235.
72. Wallace JL (1997). Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 112: 1000-1016.
73. Wallace JL, Del Soldato P (2003). The therapeutic potential of NO-NSAIDs. Fundam Clin Pharmacol 17: 11-20.
74. Wallace JL, Devchand PR (2005). Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defence. Br J Pharmacol 145: 275-282.
75. Wallace JL, Granger DN (1996). The cellular and molecular basis of gastric mucosal defense. FASEB J 10: 731-740.
76. Wallace JL, Arfors K-E, McKnight GW(1991). A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit. Gastroenterology 100: 878-883.
77. Wallace JL, Caliendo G, Santagada V, Cirino G, Fiorucci S (2007). Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulphide-releasing diclofenac derivative in the rat. Gastroenterology 132: 261-271.
78. Wallace JL, Ignarro LJ, Fiorucci S (2002). Potential cardioprotective actions of nitric oxide-releasing aspirin. Nature Rev Drug Discov 1: 375-382.
79. Wallace JL, Keenan CM, Granger DN (1990). Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophildependent process. Am J Physiol 259: G462-G467.
80. Wallace JL, McKnight W, Del Soldato P, Baydoun AR, Cirino G (1995). Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest 96: 2711-2718.
81. Wallace JL, McKnight W, Miyasaka M, Tamatani T, Paulson J, Anderson DC et al. (1993). Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. Am J Physiol 265: G993-G998.
82. Wallace JL, McKnight W, Reuter BK, Vergnolle N (2000). NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119: 706-714.
83. Wallace JL, Muscara MN, de Nucci G, Zamuner S, Cirino G, del Soldato P et al. (2004). Gastric tolerability and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen derivative, NCX-2216 [3-[4-(2-fluoro-α-methyl-[1,1′-biphenyl]-4-acetyloxy)-3- methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester]. J Pharmacol Exp Ther 309: 626-633.
84. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham M, Cirino G (1994a). A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol 257: 249-255.
85. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G (1994b). Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 107: 173-179.
86. Wallace JL, Rizzo G, Cirino G, Del Soldato P, Fiorucci S (2004). Enhanced anti-inflammatory potency of a nitric oxide-releasing derivative of flunisolide: role of nuclear factor-κB. J Pharmacol Exp Ther 310: 1096-1102.
87. Wallace JL, Vergnolle N, Muscara MN, Asfaha S, Chapman K, McKnight W et al. (1999). Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology 117: 557-566.
88. 2S be the third endogenous gaseous transmitter? FASEB J 16: 1792-1798.
89. Whiteman M, Armstrong JS, Chu SH, Siau JL, Wong BS, Cheung NS et al. (2004). The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite 'scavenger'? J Neurochem 90: 765-768.
90. Whiteman M, Cheung NS, Zhu YZ, Chu SH, Siau JL, Wong BS et al. (2005). Hydrogen sulphide: a novel inhibitor of hypochlorous acid-mediated oxidative damage in the brain? Biochem Biophys Res Commun 326: 794-798.
91. Williams JL, Borgo S, Hasan I, Castillo E, Traganos F, Rigas B (2001). Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Res 61: 3285-3289.
92. Wu WP, Hao JX, Ongini E, Impagnatiello F, Presotto C, Wiesenfeld-Hallin Z et al. (2004). A nitric oxide (NO)-releasing derivative of gabapentin, NCX 8001, alleviates neuropathic pain-like sulphide after spinal cord and peripheral nerve injury. Br J Pharmacol 141: 65-74.
93. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (1991). Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88: 2692-2696.
94. Yusuf M, Kwong Huat BT, Hsu A, Whiteman M, Bhatia M, Moore PK (2005). Streptozotocin-induced diabetes in the rat is associated with enhanced tissue hydrogen sulphide biosynthesis. Biochem Biophys Res Commun 333: 1146-1152.
95. Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL (2006). Hydrogen sulphide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J 20: 2118-2120.
96. Zarraga IG, Schwarz ER (2007). Coxibs and heart disease: what we have learned and what else we need to know. J Am Coll Cardiol 49: 1-14.